• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Good times lie ahead

Quote

anonymous

Guest
OK, so I haven’t been on board since day one I’ve been here for a while. We’ve been through some tough times but now we’re really on to clear sailing. The financial picture of the company looks a lot better thanks to astute moves by management. The outcomes data is leading to much better formulary positioning, and clearly gives us a better platform to sell from. I’m optimistic, we’re starting to see a nice jump in Rx, make some hay here as the sun is shining!
 






Recently on board and enjoying it, quota seems very low based on upside potential, but a lot of people don’t have the relationships I’ve got, virtually 100% unfettered access. Life is good.oooooo
 




anonymous said:
OK, so I haven’t been on board since day one I’ve been here for a while. We’ve been through some tough times but now we’re really on to clear sailing. The financial picture of the company looks a lot better thanks to astute moves by management. The outcomes data is leading to much better formulary positioning, and clearly gives us a better platform to sell from. I’m optimistic, we’re starting to see a nice jump in Rx, make some hay here as the sun is shining!
Click to expand...
How do you feel about sales leadership and when do you think it will hit an Inflection point like DSE in Europe?
 








anonymous said:
Recently on board and enjoying it, quota seems very low based on upside potential, but a lot of people don’t have the relationships I’ve got, virtually 100% unfettered access. Life is good.oooooo
Click to expand...
So are you the second coming of the Scientific Hiring Process, that brought a Highly Tenured Customer facing Team ?
You sound " Highly Tenured".
 




anonymous said:
How do you feel about sales leadership and when do you think it will hit an Inflection point like DSE in Europe?
Click to expand...
Sales leadership is solid, I do think that we’re set up for a sale and that’s where Sheldon will make his final mark with this company. The inflection point here in the state is not far off, and that’s when the bidding war will really start, but at the end, I think it will be a DSI deal. A lot of people think that a deal will happen in the next 6 to 9 months, and I agree.
 




Most of what I’m hearing is inline with these comments, the ramp has been slower to materialize but it’s all about managed care coverage and that’s coming along nicely. The next year will be interesting to see unfold. My manager isn’t the best but I’ve had worse before, the executive team has a pretty good list of accomplishments over the past year and this is not yet reflected in the stock.
 




ANN ARBOR, Mich., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Esperion today announced that NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) have achieved additional coverage on national and large regional formularies since the U.S. Food and Drug Administration's (FDA) approval of the expanded indications, increasing total coverage to more than 136 million commercially insured lives (92% of all commercial lives) and 34 million Medicare lives (65% of all Medicare lives). Additionally, many payers have accelerated alignment of utilization management criteria since the FDA approval of the expanded indications to the new labels.

Go Baby Go!
 




A lot of people think we’re gonna be profitable within a year, and there are still calls out there for this franchise to be a blockbuster i.e. exceeding billion dollars annually. There are more bunnies in the hat that are gonna pop out over the next couple years that will make this really interesting to watch. Right now we’ve got a ton of on tap potential and a huge market, and now with manage care access being quite good., The sky is the limit.
 




There’s no question that we’re at a tipping point, and while the initial slog has been long and hard, we know we are on the cusp of greatness. Our professional approach to this significant market opportunity has paved the way for us to make a permanent mark in the record books for the prevention of cardiovascular disease, still the number one killer in the USA. There are both intrinsic and external rewards for our work, seeing explosive growth is quite exciting. The next report should very well reflect the breakthroughs that we’ve experienced over the past year.
 




anonymous said:
There’s no question that we’re at a tipping point, and while the initial slog has been long and hard, we know we are on the cusp of greatness. Our professional approach to this significant market opportunity has paved the way for us to make a permanent mark in the record books for the prevention of cardiovascular disease, still the number one killer in the USA. There are both intrinsic and external rewards for our work, seeing explosive growth is quite exciting. The next report should very well reflect the breakthroughs that we’ve experienced over the past year.
Click to expand...
Who wants to take ownership of this nonsense post.
 








anonymous said:
Who wants to take ownership of this nonsense post.
Click to expand...
I take complete ownership of everything I post! Even though I am paid to be here, I 100% believe Esperion is going to make us all millionaires. Sheldon is in the process of working out the deal of the millennia. I hope you all chose to purchase stock during the last offering. I personally think Daichii will come out on top, but there will be a bidding war, for sure.
 




anonymous said:
I take complete ownership of everything I post! Even though I am paid to be here, I 100% believe Esperion is going to make us all millionaires. Sheldon is in the process of working out the deal of the millennia. I hope you all chose to purchase stock during the last offering. I personally think Daichii will come out on top, but there will be a bidding war, for sure.
Click to expand...
Lol.
So sure.
Ask Sheldon now for 50% of your millions.
He can keep the rest. Bet he won't.
 




Top Bottom
Back
Quote